A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Lifastuzumab vedotin (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Genentech
- 01 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History